07:00 , May 20, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) Cas-Br-M ecotropic retroviral transforming sequence b (CBLB) Genomewide association studies have identified a...
07:00 , Oct 15, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Cas-Br-M ecotropic retroviral...
08:00 , Jan 22, 2007 |  BC Week In Review  |  Company News

Cleveland BioLabs, Roswell Park Cancer Institute deal

CBLI will receive about $3 million from the institute and up to $2 million from other New York state agencies toward development of the company's CBLC 102 to treat cancer and CBLB 502 and...